Streetbeat News

AKAN

Akanda Corp.

https://www.akandacorp.com

Industry

Drug Manufacturers - Specialty & Generic

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and internationally. It intends to supply cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Akanda Corp. (NASDAQ:AKAN) shares rose after announcing plans to explore Bitcoin, blockchain, and AI applications in the cannabis industry, aiming to address banking issues and enhance product traceability and research. The company also closed a $5 million public offering, with intentions to reduce debt and expand, particularly through its UK business and technology segments.

Portfolio Pulse from Erica Kollmann

March 28, 2024 | 5:02 pm

Akanda Corp. announced that Canmart, its wholly-owned subsidiary, plans to integrate social shopping technology on Facebook and Instagram, aiming to enhance its market presence and customer engagement.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:11 pm

Akanda Corp. announced its plan to explore opportunities in Bitcoin, Blockchain, and AI applications within the cannabis industry, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 1:18 pm

Akanda Corp. has announced its strategic plan to explore and potentially enter the Bitcoin, blockchain, and AI segments within the cannabis market. This move aims to leverage emerging technologies to innovate and possibly enhance its market position in the cannabis industry.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 1:18 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Avalo Therapeutics led the gainers with a 328.2% increase, while NuCana experienced the largest drop among the losers, declining by 19.8%. Other notable movers include Xilio Therapeutics with a 223.94% increase and Akanda with a 27.1% rise. On the downside, Yield10 Bioscience and Sonoma Pharmaceuticals saw declines of 10.51% and 10.48%, respectively.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 12:06 pm

U.S. stocks showed mixed performance with the Nasdaq turning higher, while the Dow and S&P 500 fell. Energy shares led gains, while industrials lagged. Notably, Landos Biopharma surged 169% after an acquisition announcement by AbbVie. Nkarta and Altamira Therapeutics also saw significant gains. Conversely, Sintx Technologies, Akanda Corp., and Fisker Inc. experienced sharp declines. Sales of new single-family houses in the U.S. slightly fell, missing market estimates.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 7:00 pm

Landos Biopharma, Inc. (LABP) shares surged over 170% following acquisition news by AbbVie Inc. (ABBV). Other stocks also showed significant movement in Monday's mid-day session, with notable gainers including Next.e.GO N.V. (EGOX), Altamira Therapeutics Ltd. (CYTO), and MicroAlgo Inc. (MLGO), among others. Losers for the day included Sintx Technologies, Inc. (SINT), Akanda Corp. (AKAN), and Fisker Inc. (FSR), with declines attributed to various factors such as public offerings and terminated negotiations.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 6:44 pm

Health care stocks experienced significant movements in Monday's intraday session. Landos Biopharma's shares surged by 173.9% following their Q4 earnings report. Other notable gainers include Altamira Therapeutics, XTL Biopharmaceuticals, Nkarta, Sagimet Biosciences, and Molecular Templates. On the downside, Trxade Health led the losers with a 48.6% drop, followed by declines in SINTX Techs, Akanda, Invivyd, 180 Life Sciences, and Kineta.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 5:31 pm

U.S. stocks traded lower with the Dow Jones, NASDAQ, and S&P 500 all seeing declines. Energy shares rose by 1%, while communication services fell by 0.5%. Sales of new single-family houses in the U.S. dropped slightly. Landos Biopharma's stock surged 170% after announcing AbbVie will acquire it. Nkarta and Altamira Therapeutics also saw significant gains, while Sintx Technologies, Akanda Corp., and Fisker Inc. experienced sharp declines.

Portfolio Pulse from Avi Kapoor

March 25, 2024 | 4:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.